Circulating Tumor DNA Response and Minimal Residual Disease Assessment in DNA Polymerase Epsilon-Mutated Colorectal Cancer Undergoing Immunotherapy-Reference-Cited by-同舟云学术

Circulating Tumor DNA Response and Minimal Residual Disease Assessment in DNA Polymerase Epsilon-Mutated Colorectal Cancer Undergoing Immunotherapy

Published:2023-08-12 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Lutfi Areeb,Afghan Maaz K,Kasi Pashtoon M

Publisher

Springer Science and Business Media LLC

Subject

Aerospace Engineering

Reference25 articles.

1. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer;André T;N Engl J Med,2020

2. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. Accessed July 19, 2023. (2018). Accessed. July 19, 2023: https://iris.unito.it/handle/2318/1669348.

3. Colorectal cancer;Dekker E;Lancet,2019

4. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group Co.26 study;Chen EX;JAMA Oncol,2020

5. PD-1 blockade in tumors with mismatch-repair deficiency;Le DT;N Engl J Med,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer;Annals of Oncology;2024-07

2. A panorama of colon cancer in the era of liquid biopsy;The Journal of Liquid Biopsy;2024-06

3. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer;The Oncologist;2024-05-22

4. Tumor mutational burden in colorectal cancer: Implications for treatment;Critical Reviews in Oncology/Hematology;2024-05